136 related articles for article (PubMed ID: 32169872)
21. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
24. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
Perez Horta Z; Goldberg JL; Sondel PM
Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
26. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.
Schlesinger JJ; Foltzer M; Chapman S
Virology; 1993 Jan; 192(1):132-41. PubMed ID: 8517015
[TBL] [Abstract][Full Text] [Related]
27. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas.
Greiner JW; Guadagni F; Hand PH; Pestka S; Noguchi P; Fisher PB; Schlom J
Cancer Treat Res; 1990; 51():413-32. PubMed ID: 1977458
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
31. Positron Emission Tomography Detects
Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
33. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model.
Baniel CC; Sumiec EG; Hank JA; Bates AM; Erbe AK; Pieper AA; Hoefges AG; Patel RB; Rakhmilevich AL; Morris ZS; Sondel PM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115944
[TBL] [Abstract][Full Text] [Related]
35. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
36. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
37. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.
Ritter G; Cohen LS; Williams C; Richards EC; Old LJ; Welt S
Cancer Res; 2001 Sep; 61(18):6851-9. PubMed ID: 11559561
[TBL] [Abstract][Full Text] [Related]
38. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
39. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
40. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
Suitters AJ; Foulkes R; Opal SM; Palardy JE; Emtage JS; Rolfe M; Stephens S; Morgan A; Holt AR; Chaplin LC
J Exp Med; 1994 Mar; 179(3):849-56. PubMed ID: 8113678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
